Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a Research Technician to join our team at the Champalimaud Research Programme. 

Meeting Description

This meeting collaboration between the Association for Cancer Immunotherapy CIMT and the Champalimaud Foundation will address promising paths towards effective cellular treatment modalities for patients with solid cancer and discuss the boundaries of synthetically engineered immune cells. The meeting will also discuss the innovation gap between academic and small biotech driven research, and the challenges of safe, biologically, and clinically relevant phase I / II clinical trials. 

Description

Nuno Prego Ramos, co-founder and CEO of CellmAbs, will share the journey of CellmAbs, from it's early days starting with an initial technology from NOVA University to becoming a pioneering force in cancer therapy innovation.

In this talk, we will hear about the strategic decisions, challenges and breakthroughs that propelled the company to its selling the assets to the pharmaceutical giant, BioNTech.

“When I explain to my friends and family the rigorous regulations in place to ensure ethical treatment of experimental animals, they seem surprised.
 
It is important that people know that researchers that use animals are obliged to have appropriate qualifications and training. That scientific projects are evaluated to ensure that the use of animals is needed, beneficial and that no unnecessary harm is inflicted. And that the highest standards of housing conditions must be provided by the facilities where animals are housed.
 

Reported today in Science, the researchers found that mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment. This effect was also seen when gene editing was used to remove a protein that binds to vitamin D in the blood and keeps it away from tissues.

Host

Carlos Minutti, Principal Investigator, Champalimaud Research

Venue

Seminar room

Do you know all about Non-Melanoma Skin Cancer (NMSC)?

We are thrilled to announce that the registrations for the NMSC Symposium “Non-Melanoma Skin Cancer. What do we know?”, hosted by the Champalimaud Foundation on the 7th of June, are now open!

This event will be a fusion of clinical expertise and research advancements, bringing together experts and healthcare professionals to discuss the latest research findings and clinical developments in the diagnosis and treatment of Non-Melanoma Skin Cancer.

There are varying degrees in the response of a cancerous tumour to a treatment. A complete response corresponds to the disappearance of all detectable signs of cancer in the body, while a partial or incomplete response is a decrease in the size of the tumour or in the amount of cancer in the body. To be considered a partial response, the measurable size of the tumor has to be reduced by at least 30% to 50% due to the treatment. 

This Sunday, April 14th, to commemorate four years since her passing, the Champalimaud Foundation honoured the memory of researcher Maria de Sousa, renowned globally as a pivotal figure in the field of Immunology.

The ceremony took place at the Champalimaud Foundation, with the inauguration of an exhibition showcasing an art collection by Pedro Cabrita Reis, representing Maria de Sousa's research and inspired by her curiosity and permanent quest for knowledge.

A strategy called Watch & Wait (W&W) has increasingly been used, including at the Champalimaud Foundation, to avoid surgery and its associated complications, in a selected group of patients  whose tumours become undetectable after chemoradiotherapy. In terms of the local tumour control, it has been shown to be as safe to operate them later – if ever their tumour gives any sign of coming back – as to operate them immediately after chemoradiotherapy treatment.